Intercept Pharmaceuticals beats in Q2, keeps full-year outlook unchanged
Intercept Pharmaceuticals (NASDAQ: ICPT) on Wednesday reported second-quarter results that surpassed Wall Street expectations, riding on the strong growth of its liver treatment Ocaliva. Second-quarter…